Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The objectives were to monitor the 36-month, interim efficacy and safety results of the ongoing extension o...
Alternative Titles
Full title
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_00617800v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_00617800v1
Other Identifiers
ISSN
1352-4585
E-ISSN
1477-0970
DOI
10.1177/1352458509357065
